FIBROUS MEMBRANES IN DIABETIC RETINOPATHY AND BEVACIZUMAB

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Retina

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/IAE.0b013e3181cb463aPMID 20616680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up

  2009cited by this paper
• Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

  2009cited by this paper
• Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high‐risk proliferative diabetic retinopathy (IBeHi study)

  2008cited by this paper
• Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy

  2008cited by this paper
• Intravitreal bevacizumab (Avastin®) in proliferative diabetic retinopathy

  2008cited by this paper
• Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.

  2008cited by this paper
• Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema

  2008cited by this paper
• Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)

  2008cited by this paper
• Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

  2007cited by this paper
• Platelets Take Up the Monoclonal Antibody Bevacizumab

  2007cited by this paper
• Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin)

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGE

  2006cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)

  2006cited by this paper
• EVALUATION OF IN VITRO EFFECTS OF BEVACIZUMAB (AVASTIN) ON RETINAL PIGMENT EPITHELIAL, NEUROSENSORY RETINAL, AND MICROVASCULAR ENDOTHELIAL CELLS

  2006cited by this paper
• Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

  2006cited by this paper
• Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

  2004cited by this paper
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

  2004cited by this paper
• Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells.

  2001cited by this paper
• RELATIONSHIPS BETWEEN THE ENDOTHELIN AND NITRIC OXIDE PATHWAYS

  1999cited by this paper
• Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells.

  1998cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• Cytokeratin-containing cells in proliferative diabetic retinopathy membranes.

  1994cited by this paper

• Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy

  2024cites this paper
• Effect of intravitreal ranibizumab on fibrovascular membranes in patients with proliferative diabetic retinopathy.

  2022cites this paper
• Cell–Matrix Interactions in the Eye: From Cornea to Choroid

  2021cites this paper
• APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2

  2017cites this paper
• A novel role for coagulation proteins in the development of proliferative vitreoretinopathy

  2015cites this paper
• Bevacizumab modulates the process of fibrosis in vitro

  2015cites this paper
• GENOMIC AND PROTEOMIC CHARACTERIZATION OF PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS IN THE HUMAN EYE

  2014cites this paper
• Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic

  2013cites this paper
• Functional and Molecular Characterization of Ex Vivo Cultured Epiretinal Membrane Cells from Human Proliferative Diabetic Retinopathy

  2013cites this paper
• Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy.

  2013cites this paper
• ALTERED VASCULAR MICROENVIRONMENT BY BEVACIZUMAB IN DIABETIC FIBROVASCULAR MEMBRANE

  2013cites this paper
• In Vitro Coagulation Effects of Ophthalmic Doses of Bevacizumab

  2012influential citation
• Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α

  2012cites this paper
• Pathology of vitreoretinal junction biopsies

  2011cites this paper
• Treatment of proliferative diabetic retinopathy with anti‐VEGF agents

  2011cites this paper
• Retro-mode imaging of fibrovascular membrane in proliferative diabetic retinopathy after intravitreal bevacizumab injection

  2011cites this paper